School of Public Health Is Testing New Vaccine to Prevent Anthrax
By Tim Parsons
School of Public Health
The Johns Hopkins Bloomberg School of Public Health is one of 12 sites testing a new vaccine to prevent anthrax. The phase II trial will evaluate the safety and immunogenic response of a new recombinant anthrax vaccine, known as rPA102. The vaccine candidate consists of recombinant protective antigen, a synthetic protein that induces antibodies designed to prevent illness by neutralizing anthrax toxins, and aluminum hydroxide to enhance the immune response. Different formulations of rPA102 will be given to 480 healthy volunteers. Each formulation will contain varying concentrations of rPA.
Article: http://www.jhu.edu/~gazette/2004/19jul04/19anthra.html